阿瑞匹坦对黑色素瘤患者顺铂治疗引起恶心呕吐的止吐作用
DOI: 10.3971/j.issn.1000-8578.2015.07.015
唐碧霞,
崔传亮,
斯璐,
李思明,
毛丽丽,
王轩,
盛锡楠,
连斌,
迟志宏,
郭军,
鄢谢桥
Keywords: New Target of Immunotherapy for Esophageal Cancer,Effects of Ganoderma Lucidum Polysaccharide on Chemotherapy Effect and Immune Escape in T24 Bearing Mice,Comparison of Acute Toxicity between Intensity-modulated Radiotherapy with Cisplatin Alone Concurrent Chemotherapy Weekly and Every Three Weeks for Nasopharyngeal Carcinoma Patients,Protective Effect of Grape Seed Proanthocyanidin Extract on Cisplatin-induced Damage in Mice Testes Sertoli Cells TM4,Effect of Endoplasmic Reticulum Status on Sensitivity of Ovarian Cancer Cells to Cisplatin,Short-term Effect of Endostar/Bevacizumab in Combination with Paclitaxel and Platinum for Advanced Lung Adenocarcinoma,Cisplatin-induced Senescence and Senescence-related Gene Expression Profiles in#br# Human Nasopharyngeal Carcinoma Cells CNE2,Inhibition of Cilengitide on Tumor Growth of A Nude Mouse Model with Lung#br# Adenocarcinoma Cell Line A549 and Its Mechanism,Effects of Bufalin on Proliferation and Apoptosis of Melanoma Cells B16
Abstract:
摘要 目的 旨在探讨阿瑞匹坦对黑色素瘤患者顺铂治疗引起的恶心呕吐的作用。方法 170例接受含顺铂方案治疗的黑色素瘤患者，随机分入阿瑞匹坦组和对照组进行预防性止吐治疗。记录患者顺铂治疗后的恶心、呕吐反应，解救治疗，功能性生活指数（呕吐）及其他不良反应。结果 两组中各84例患者可评价疗效。阿瑞匹坦组患者的完全缓解率（无呕吐，无解救治疗）为69%，显著高于对照组的44%（χ2=10.683，P=0.001）。阿瑞匹坦组和对照组的呕吐发生率分别为27%和51%，阿瑞匹坦组显著优于对照组（χ2=9.982，P=0.002）。阿瑞匹坦组未观察到相关的不良反应。结论 阿瑞匹坦可显著降低黑色素瘤患者中顺铂引起的呕吐反应。尽管阿瑞匹坦的安全性良好，在给药前仍需注意药物间的相互作用
Full-Text
